spacer State Government Victoria Australia Department of Health header
Victorian Government Health Information header
Victorian Government Website (Victoria the place to be)
spacer
spacer Health Home
Main A to Z Index | Site Map | About Health | Links  
Hospital Circulars

Hospital Circulars Main Index < Hospital Circulars 2009 Index <

Hospital Circular 28/2009

Date Issued: 26 October 2009

Distribution: Public Hospitals

Subject:Highly Specialised Drugs Program

To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 November 2009.


We have received recent advice from the Commonwealth Department of Health and Ageing regarding changes to the Highly Specialised Drugs Program, effective 1 November 2009.

ADDED DRUG

LENALIDOMIDE

9642L Capsule 5mg 21 $5,392.38 Revlimid CJ
9643M Capsule 10mg 21 $5,643.33 Revlimid CJ
9644N Capsule 15mg 21 $6,581.61 Revlimid CJ
9645P Capsule 25mg 21 $6,934.20 Revlimid CJ

Note: Special pricing arrangements apply

Public hospital authority required

Initial treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has progressive disease, who has received at least 1 prior therapy (other than thalidomide), who has undergone or is ineligible for a primary stem cell transplant and who has experienced treatment failure after a trial of a least four weeks of thalidomide at a dose of a least 100mg daily.

Continuing treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.                              

Full prescribing criteria for all listed items including the above is available at: http://www.health.vic.gov.au/hsdp/app2.htm

ADDED ITEMS

APOMORPHINE HYDROCHLORIDE

96478R Solution for s/c infusion 50mg in 10mL pre-filled syringe 5 $194.65 Apomine PFS HH

ATAZANAVIR

9646Q Capsule 100mg (as sulphate) 60 $347.94 Reyataz BQ

RESTRICTION ALTERATIONS

DORNASE ALFA

Now includes – “Treatment of cystic fibrosis in a patient less than 5 years of age”

ETANERCEPT

Removal of authority condition for continuing treatment if treatment started prior  to 1 December 2002.

Full prescribing criteria for all listed items including all the above is available at: http://www.health.vic.gov.au/hsdp/app2.htm

DELETED ITEMS

RIBAVIRIN and PEGINTERFERON ALFA-2a

6389G Pack containing 84 tablets ribavirin 200mg and 4 pre-filled syringes peginterferon alfa-2a injection 135mcg Pegasys RBV RO

RIBAVIRIN and PEGINTERFERON ALFA-2a

6390H Pack containing 112 tablets ribavirin 200mg and 4 pre-filled syringes peginterferon alfa-2a injection 135mcg Pegasys RBV RO

RIBAVIRIN and PEGINTERFERON ALFA-2a

6391J Pack containing 140 tablets ribavirin 200mg and 4 pre-filled syringes peginterferon alfa-2a injection 135mcg Pegasys RBV RO

Items discontinued by manufacturer.

Full prescribing criteria for all listed items including the above is available at: http://www.health.vic.gov.au/hsdp/app2.htm
                                                                                                                       

Changes notified by hospital circular will be updated in the Guidelines on the internet and the relevant claim forms amended. 

WEB SITE ADDRESS:      www.health.vic.gov.au/hsdp

Geoff Lavender
Director, Programs
Metropolitan Health & Aged Care Services



Last updated: 2 November, 2009
This web site is managed and authorised by the Metropolitan Health and Aged Care Services Division of the Victorian State Government, Department of Health, Australia

Copyright | Disclaimer | Privacy Statement | State Government of Victoria Home | Download Help

For general enquiries to the Department of Health telephone 61 3 90960000